Cargando…
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors
BACKGROUND: Patients with cancer, especially hematological cancer, are at increased risk for breakthrough COVID-19 infection. So far, a predictive biomarker that can assess compromised vaccine-induced anti-SARS-CoV-2 immunity in cancer patients has not been proposed. METHODS: We employed machine lea...
Autores principales: | Konnova, Angelina, De Winter, Fien H. R., Gupta, Akshita, Verbruggen, Lise, Hotterbeekx, An, Berkell, Matilda, Teuwen, Laure-Anne, Vanhoutte, Greetje, Peeters, Bart, Raats, Silke, der Massen, Isolde Van, De Keersmaecker, Sven, Debie, Yana, Huizing, Manon, Pannus, Pieter, Neven, Kristof Y., Ariën, Kevin K., Martens, Geert A., Bulcke, Marc Van Den, Roelant, Ella, Desombere, Isabelle, Anguille, Sébastien, Berneman, Zwi, Goossens, Maria E., Goossens, Herman, Malhotra-Kumar, Surbhi, Tacconelli, Evelina, Vandamme, Timon, Peeters, Marc, van Dam, Peter, Kumar-Singh, Samir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813584/ https://www.ncbi.nlm.nih.gov/pubmed/36618384 http://dx.doi.org/10.3389/fimmu.2022.1062136 |
Ejemplares similares
-
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
por: Peeters, M., et al.
Publicado: (2021) -
Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients
por: van Dam, P.A., et al.
Publicado: (2022) -
1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients
por: Debie, Y., et al.
Publicado: (2022) -
Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients
por: De Winter, Fien H. R., et al.
Publicado: (2021) -
36P Alterations in tumour-promoting cytokines in cancer patients after SARS-CoV-2 infection
por: De Winter, F.H., et al.
Publicado: (2021)